Xcout Intel
Orbus Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Orbus Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Orbus Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Orbus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. is a pharmaceutical company headquartered in Menlo Park, California, dedicated to developing treatments for rare forms of cancer, including clinical trials for brain tumors.
Orbus Therapeutics, Inc. at a glance
Orbus Therapeutics, Inc. is a biotechnology company headquartered in United States, founded in 2012. Its most recent funding round raised $10M in July 2020. Xcout tracks 8 named people at Orbus Therapeutics, Inc., including Jackie Walling (CHIEF MEDICAL OFFICER (CONSULTANT)).
Orbus Therapeutics, Inc. leadership
- Jackie WallingCHIEF MEDICAL OFFICER (CONSULTANT)
- Noymi Yam, PhDVICE PRESIDENT, CHIEF SCIENTIFIC OFFICER
- Jason LevinFounder, Director and chief executive officer
- Jennifer EkelundHEAD, REGULATORY AFFAIRS AND QUALITY ASSURANCE
- Alex ZissonManaging Director, H.I.G. HealthBridge Partners
- Patrick EnrightManaging Director, Longitude Capital
2 more named people on record for Orbus Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Orbus Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10M | — | |
| Series A | $10M | 4 named | |
| SEC Form D filing | $18.5M | — | |
| SEC Form D filing | $18M | — | |
| Series A | $32.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Orbus Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Orbus Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Similar biotechnology company
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
Similar biotechnology company
Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.
Similar biotechnology company
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Biotech
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Life Sciences & Healthcare
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cancer therapies, with a focus on diseases affecting children and adults. Its lead product, tovorafenib (Ojemda), is an FDA-approved treatment for pediatric patients with relapsed or refractory low-grade glioma harboring qualifying BRAF alterations.
Similar biotechnology company
InCephalo Therapeutics is a privately held biotechnology startup founded in 2021 and headquartered in Switzerland, with operations based in Schlieren and Allschwil. The company develops innovative, exclusively local treatments specifically targeting brain cancers.
Similar biotechnology company
PIC Therapeutics, Inc. is a biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to developing life-changing medicines for patients with cancer. The company focuses on oncology research and therapeutic product development.
Similar biotechnology company
Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.
Biotech
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Biotech
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Similar biotechnology company
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Orbus Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Orbus Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →